SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is facing significant downward pressure following an orbital anomaly during a Blue Origin launch that resulted in the loss of a satellite. While the company confirmed that insurance will cover the loss and that production of upcoming units remains on track, investors are expressing deep concern over potential timeline delays and the reliability of launch partners.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Invesco QQQ Trust is trending as traders closely monitor escalating geopolitical tensions in the Middle East alongside conflicting headlines regarding potential peace talks. Market participants are actively debating whether this volatility signals an impending pullback from recent highs or if algorithmic buying and tech earnings momentum will continue to drive a melt-up.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical Ltd. (PBM) is experiencing significant volatility and trading momentum driven by speculation surrounding a potential executive order aimed at fast-tracking psychedelic research for veteran mental health. Investors are heavily focused on the stock's low float and potential for a short squeeze, leading to heated discussions between bullish retail traders anticipating triple-digit price action and skeptical bears warning of a possible pump-and-dump scenario.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is trending as investors monitor significant developments in the rare earths supply chain, including new commercial yttrium metal production and ongoing discussions regarding government funding and critical mineral trade agreements. The community is actively debating the company's valuation, potential technical breakout patterns, and the impact of geopolitical factors on domestic production capabilities.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as community members closely monitor the upcoming AACR poster presentation for SLS009 and anticipate a final data readout for the REGAL Phase 3 trial. Long-term investors are expressing high confidence in the potential for a functional cure, while the stock is seeing significant volatility driven by intense debate over short interest levels and options positioning.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors monitor high trading volume and potential catalysts related to the companys global expansion in Japan and the Middle East, while community members actively discuss the long-term potential of the Anktiva platform to disrupt the oncology sector. Conversations are heavily focused on the contrast between the stock's clinical progress and the regulatory scrutiny from the FDA, with many shareholders maintaining conviction in the companys pipeline despite ongoing short-term market volatility.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending as market sentiment surges following news that the White House issued an executive order to expedite psychedelic research and FDA review pathways. The community is actively discussing the stock's positioning as a late-stage clinical leader, with many investors debating the potential for an accelerated regulatory approval process to reshape the mental health sector.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is currently trending following an update on the open-label arm of its FLAMINGO-01 Phase III trial, which demonstrated a recurrence rate of less than 1% annually, representing a significant reduction compared to historical benchmarks. Investors are heavily focused on the company's progress toward the 14-event interim analysis and the upcoming AACR meeting, where a steering committee-backed abstract is expected to provide deeper insights into the drug's clinical efficacy.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The S&P 500 is facing heightened volatility as investors weigh renewed geopolitical tensions in the Strait of Hormuz against persistent market complacency. The community remains sharply divided, with bulls betting on institutional propping and government-led market support, while bears express concern over potential supply shocks and the sustainability of recent price gains.

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

$4CHAN is trending as the community doubles down on its identity as the cultural "index" of meme tokens, emphasizing its origin as the birthplace of major internet memes. Enthusiasts are actively discussing tokenomics, such as blacklisted wallets and high supply, while viewing recent price action as a long-term accumulation phase for an asset they believe will eventually outpace traditional meme coins.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IBRX

ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IBRX ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to...

<ul class="summary-bullets"><li>The founder said Trump “can make huge advances in transforming the health of Americans” following a White House push to accelerate psychedelic-therapy research.</li><li>He flagged evidence showing over 2x higher distant breast cancer recurrence risk in remission patients with lymphopenia, or reduced levels of key immune cells.</li><li>Further trials are planned to test whether post-COVID immune dysfunction associated with T-cell exhaustion can be reversed with Anktiva.</li></ul>Shares of ImmunityBio, Inc. (IBRX) drew fresh attention over the weekend after founder Patrick Soon-Shiong backed U.S. President Donald Trump’s psychedelic-policy push and flagged new data linking low immune-cell levels to a higher risk of breast-cancer recurrence, spotlighting Anktiva.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> snapped a three-week losing streak to end last week up 6%.<h2 class="st-heading-2">IBRX Founder Backs Trump Psychedelic Push</h2>Soon-Shiong responded over the weekend to a White House push to accelerate research into psychedelic therapies, including ibogaine,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2045586218315055363">saying on X</a> that the president “can make huge advances in transforming the health of Americans.”The remarks followed an executive order directing federal support toward state-level programs advancing psychedelic treatments for serious mental illness. The development, alongside a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrMakaryFDA/status/2045631018657370381">post on X</a> from FDA Commissioner Marty Makary that the agency is “moving proactively to advance potential therapies to address America’s mental health crisis,” a post Soon-Shiong also shared.Podcast host Joe Rogan said during the ceremony he had earlier texted Trump about ibogaine’s addiction-treatment potential and recalled the president replying, “Sounds great. Do you want FDA approval? Let’s do it.”<h2 class="st-heading-2">New Breast Cancer Risk Data</h2>In a separate weekend update, Soon-Shiong pointed to new findings linking lymphopenia, or reduced levels of key immune cells, to higher recurrence risk in patients with early-stage breast cancer in remission.“News will break tomorrow,” he&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2045665757665890677">said</a>. “Evidence of an INCREASE OF OVER 2 TIMES THE RISK of distant recurrence of breast cancer (in patients in remission) with lymphopenia (low TCells and low NK cells).” He added that absolute lymphocyte count “matters in patients in remission with early stage (1 to 3) breast cancer” and called it an “easy test to monitor lymphopenia and to address this increased risk.”Soon-Shiong later cited independent research presented by UCLA breast cancer oncologist Aditya Barda at the American Association for Cancer Research (AACR) meeting,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2045947022528934137">saying</a> that the data showed that “regardless of the stage of BREAST CANCER, that post Covid lymphopenia results in poorer prognosis, poorer response to treatment and even 2x higher recurrence when patients are in remission.”“The relationship of low NK and low T cells to breast cancer (and frankly all cancers) is so clear,” he added, calling the findings “very compelling.”<h2 class="st-heading-2">Trials Planned To Reverse Post-COVID Immune Dysfunction</h2>Additionally, Soon-Shiong responded to questions about how clinicians may address post-COVID lymphopenia, saying a patient is currently being treated under an FDA-authorized single-patient investigational new drug pathway.&nbsp;“This is a clinical study and not an approved indication, but we are finding what is known as T cell exhaustion,” he&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2045957658071683246">said</a>, adding that more clinical trials are planned to explore whether the condition can be reversed.The immune-cell findings are notable in the context of Anktiva, an IL-15-based immunotherapy that boosts natural killer cells and CD8 T cells, two immune cell types that help the body detect and destroy virus-infected and cancer cells.Soon-Shiong had earlier said clinicians at the University of California, Los Angeles and the Mount Sinai Health System were observing links between lymphopenia after COVID and a rising incidence of metastatic disease and cancer recurrence in patients who had previously been in remission. He added that those concerns were “being validated” by emerging data presented at the AACR summit.ImmunityBio is already evaluating Anktiva in a Phase 2 study in patients with persistent post-COVID symptoms to test whether restoring immune-cell balance may correct underlying immune dysfunction.<h2 class="st-heading-2">Founder Defends Anktiva As Policy Momentum Builds</h2>The latest updates follow recent regulatory scrutiny of Anktiva after the FDA issued a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/immunitybio-founder-fda-warning-letter-anktiva-ad-never-aired/cZJpYnYRIHR">warning letter</a> citing promotional language that referenced uses beyond the therapy’s approved indication. Soon-Shiong pushed back publicly, saying a television advertisement cited by regulators “never aired at all.”Anktiva, approved in 2024 with standard BCG for certain bladder-cancer patients who no longer respond to standard therapy, is now being studied across multiple tumor types and severe inflammatory conditions. The therapy has also expanded internationally after conditional marketing authorization from the European Commission across the European Union, plus Iceland, Liechtenstein and Norway.Soon-Shiong has previously said&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-rally-not-over-yet-chairman-says-trump-diplomacy-led-to-amazing-results-for-cancer-drug/cZRZDoZR4Dx">that talks with Trump</a> and Saudi Crown Prince Mohammed bin Salman helped accelerate regulatory progress and the global rollout of the company’s Bioshield platform, including steps supporting lung cancer approvals and regional deployment across the Middle East and North Africa.<h2 class="st-heading-2">How Do Retail Traders Feel About IBRX?</h2>On Stocktwits, retail sentiment for IBRX has improved to ‘neutral’ from ‘bearish’ levels over the past week amid a 70% jump in message volumes during the same period.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_30d9175bac.webp" alt="ibrx ss.png" width="969" height="142"><figcaption>IBRX sentiment and message volume as of April 19 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Hotresearchsgoldenage/message/650731488">said</a>, “sold a good bit Friday at 7.84 with the intention to buy my khc stock back but now I’m buying a ton of Ibrx tommorow. Don’t be a panican! A mountain of money is waiting to get in here.”<stembedurl>https://stocktwits.com/Hotresearchsgoldenage/message/650731488</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Quantum_Long/message/650729851">expressed</a> optimism for Anktiva’s broader approval in additional approvals saying, “zero doubt this is coming before the midterms.&nbsp; Trump will have the heyday of curing cancer during his term.”<stembedurl>https://stocktwits.com/Quantum_Long/message/650729851</stembedurl>IBRX stock has jumped 212% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/asts-stock-bluebird-7-orbit-failure-satellite-exit-network-buildout/cZB5uQiRIy9">ASTS Stock Slumps Overnight: BlueBird-7 Orbit Failure Forces Satellite Exit From Network Buildout</a>

Dr. Patrick Soon-Shiong arrives at Trump National Golf Club Bedminster in Bedminster Township, N.J. on Saturday, Nov. 19, 2016. (Photo by Jabin Botsford/The Washington Post via Getty Images)

IBRX Founder Backs Trump’s Psychedelic Push In ‘Transforming’ Health Policy — Flags New Anktiva Breast Cancer Risk Data

The updates follow a recent FDA warning letter on promotional claims tied to Anktiva, which the founder publicly disputed.

Equity

ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX

ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff...

IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman

IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued...

ImmunityBio (NASDAQ:IBRX) Trading Down 5.3% - Time to Sell?

ImmunityBio (NASDAQ:IBRX) Trading Down 5.3% - Should You Sell...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines - IBRX

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines - IBRX INVESTOR ALERT: Pomerantz Law Firm...

IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi...

INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces INVESTOR DEADLINE: ImmunityBio...

IBRX Lawsuit Alleges Chairman Allegedly Concealed Drug Limitation Risks - ImmunityBio Investors Face Losses Following Chairman Allegedly Concealed Drug Limitation Risks: SueWallSt

IBRX Lawsuit Alleges Chairman Allegedly Concealed Drug Limitation Risks - ImmunityBio Investors Face Losses Following Chairman Allegedly Concealed Drug Limitation Risks: SueWallSt IBRX Lawsuit...

Robbins LLP Urges IBRX Stockholders Who Lost Money Investing in ImmunityBio, Inc. to Contact the Firm for Information About Leading the Class Action

Robbins LLP Urges IBRX Stockholders Who Lost Money Investing in ImmunityBio, Inc. to Contact the Firm for Information About Leading the Class Action Robbins LLP Urges IBRX Stockholders Who Lost Money...

Bullish continuation

Sideways chop

Fade lower

Full reversal

The market rebounded fast this week — what’s your call for next week?

Stocktwits

Stocktwits Polls

Investors are closely tracking Dr. Patrick Soon-Shiong's recent trip to Japan as a strategic move to fast-track global partnerships and bypass US regulatory delays.

The community is vocal about frustration regarding the FDA's regulatory pace compared to accelerated pathways recently granted to other medical sectors.

Bullish investors are highlighting the clinical data and expanding use cases for AnkTiva as evidence of a platform that disrupts traditional oncology markets.

Discussions are heating up comparing current market caps to other speculative oncology peers, leading many to believe the stock is significantly undervalued.

The trader community is positioning for potential upside volatility, citing high short interest and pending catalysts as fuel for a significant rally.

IBRX
ImmunityBio Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IBRX News

IBRXImmunityBio Inc